The Journal of Informed Pharmacotherapy 2002;10:155
Reviewer: James McCormack, B.Sc. (Pharm), Pharm. D.
Reviewer's email address: email@example.com
Reviewer's profession/specialty: Associate Editor, Journal of Informed Pharmacotherapy
Health Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,356 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22 PubMed Citation
These investigators evaluated the benefit of treating "high risk" patients with simvastatin.
20,536 "high risk" patients (76% males, 29% at least 70 years of age). High risk was defined as patients with previous MI (41%) or CHD (24%), occlusive disease of non-coronary arteries (22%), diabetes (20%), treated hypertension (41%), PLUS a total cholesterol greater than 3.5 mmol/L. Patients could have a combination of these risk factors.
Simvastatin 40 mg PO daily or placebo.
|All deaths (%)||Any major vascular event (%)||Coronary events (%)||Strokes (%)|
|Relative Risk Reduction||12||21||26||25|
|Absolute Risk Reduction||1.8||5.4||3.1||1.4|
|NNT/NNH over 5 years||56||19||32||71|
Total cholesterol was lowered by 1.0 mmol/L on average.
Relative reductions in the primary endpoint were similar for patients regardless of sex, age, total/LDL/HDL levels, or whether or not they had had a previous MI, other CHD, CVD, PVD, or diabetes.
No differences were detected between groups for elevated liver enzymes, cancers, myopathies, fractures, or neuropsychiatric disorders.
This study shows that simvastatin given to "high risk" patients, regardless of age or sex, or baseline cholesterol levels lowers the chance of cardiovascular events.
Copyright © 2002 by the Journal of Informed Pharmacotherapy. All rights reserved.